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Abstract The complex formed between the human papilloma-
virus type 16 E6 protein and human E6-associated protein, which 
combine to ubiquitylate and degrade p53, has been studied by 
chemical crosslinking. Analysis of the interactions of proteins 
purified from Escherichia coli as well as proteins expressed in 
insect cells indicates that, while Б6 has the capacity to form 
dimers, E6 and E6-associated protein interact as two monomers 
to form a heterologous dimer. 
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1. Introduction 
Human papillomaviruses (HPV) have been implicated in 
the development of cervical carcinomas since the discovery 
of viral DNA in cervical cancer tissue and cell lines [1-3]. 
However, the transforming properties of the virus are re-
stricted to a small region of the viral genome which encodes 
the E6 and E7 open reading frames (ORFs) [4,5]. E6 is a 
small, highly basic protein which binds to the p53 tumour 
suppressor protein [6] and induces its degradation via the 
ubiquitin dependent proteolysis pathway [7]. Inactivation of 
p53 is a common mechanism involved in the development of 
cancer and it has been demonstrated that, where HPV positive 
cancers retain wild-type p53 which is inactivated by E6, HPV 
negative carcinomas express a mutant p53 [8,9]. 
The degradation of p53 requires that E6 interacts with a 
cellular protein, E6-associated protein (E6-AP), because nei-
ther protein will bind to p53 without the other [10,11]. E6 and 
E6-AP, in concert, fulfil the role of a ubiquitin protein ligase 
in the ubiquitin degradation pathway [12]. This pathway (re-
viewed in [13,14]) involves the activation of ubiquitin by the 
formation of a high energy thioester bond with the ubiquitin 
activating enzyme El. The activated ubiquitin is then trans-
ferred to a ubiquitin conjugating enzyme (E2) which was orig-
inally thought to catalyse the transfer of ubiquitin to the 
substrate protein, the recognition of which often required a 
third protein, a ubiquitin protein ligase (E3). However, recent 
evidence suggests that in some cases the E3 may be directly 
involved in the transfer of ubiquitin to the substrate [15,16]. 
This certainly seems to be the case in the E6 mediated pro-
teolysis of p53 where ubiquitin is transferred from a specific 
E2 to E6-AP and ultimately to p53 [16,17]. 
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Most of the information regarding the E6/E6-AP ubiquity-
lation of p53 has been acquired from in vitro data and the 
interaction of E6 and E6-AP has yet to be confirmed in vivo. 
This is partly due to a lack of good antibodies to both E6 and 
E6-AP which, in turn, may be a consequence of using impure 
protein preparations and also the frequent use of fusion pro-
teins that can mask potentially dominant epitopes. This latter 
point is an important factor in the development of antibodies 
against E6. We have cloned the cDNA of E6-AP from the 
cervical carcinoma cell line CaSki and have overexpressed 
both E6 and E6-AP in Escherichia coli in a soluble form. 
The two proteins have been purified to near homogeneity 
from soluble bacterial extracts and were used to produce 
highly specific, polyclonal antibodies in rabbits. Using the 
purified proteins and proteins expressed in insect cells, chem-
ical crosslinking analyses have been carried out to examine the 
stoichiometry of the interactions of E6 and E6-AP in vitro 
and ex vivo. 
2. Materials and methods 
2.1. Plasmid constructions 
The sequence for E6 was amplified from the reference viral clone by 
PCR (nts. 104-559) [18] and inserted into pT7Blue to form pT7E6. 
The cDNA for E6-AP was amplified, by RT-PCR of RNA isolated 
from CaSki cells, in two separate but overlapping halves (nts. 40-1593 
and 1183-2598 from the sequence published by Huibregtse et al. [11]). 
The products of the RT-PCR were ligated into pT7Blue to produce 
pT7APA and pT7APB. The full length construct, pT7E6-AP, was 
constructed by ligating the BamHl-Bsml restriction fragment of 
pT7APB into pT7APA that had been cut with the same enzymes. 
From their respective pT7Blue clones the E6 and E6-AP ORFs 
were ligated into the bacterial expression vector pET15b to generate 
рЕТЕб and pETE6-AP. E6 and E6-AP were also sub-cloned into a 
previously modified baculovirus transfer vector pVL941 [19]. The hu-
man p53 cDNA was amplified by PCR from the clone pT7-7Hup53 
[20] and ligated directly into pT7Blue to produce pT7p53. The entire 
nucleic acid sequences of all the clones generated were sequenced 
using an ABI 373A automated sequencer to verify that they were 
wild-type. 
2.2. Protein expression and purification 
E6 expression was induced in the host strain BL21(DE3)pLysS, 
grown in LB medium, by the addition of 1 mM IPTG for 5 h at 
25°C. Protein was purified by using immobilised metal affinity 
(IMAC), cation exchange and size exclusion chromatography techni-
ques. The histidine tag was also removed by thrombin cleavage. E6-
AP expression was induced in BL21(DE3)pLysS, grown in LB me-
dium, by the addition of 1 mM IPTG for 3 h at 25°C. The first 
purification step was by IMAC, followed by ammonium sulphate 
precipitation and then anion exchange and size exclusion chromatog-
raphy. 
2.3. Production of antisera and immunoblot analysis 
Antisera specific for HPV 16 E6 and E6-AP were prepared by 
injecting New Zealand White rabbits subcutaneously with 0.5 mg of 
purified protein emulsified in an equal volume of Freund's adjuvant. 
Antisera were affinity purified using AffiGel 10 (BioRad) according to 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793 (9 7)01160-5 
P.R. Daniels et allFEBS Letters 416 (1997) 6-10 7 
the manufacturer's instructions. E6-AP was coupled to the matrix in 
the presence of 80 mM СаСЬ. Immunoblot analysis was carried out 
essentially as described by Sanders et al. [19], and the affinity purified 
antisera were used at dilutions of 1:5000. 
2.4. Expression of recombinant proteins in insect cells 
Spodoptera frugiperda Sf21 cells were maintained in Grace's insect 
cell medium (Gibco BRL) supplemented with 10% fetal calf serum at 
27°C. Cells were routinely adapted from monolayer to spinner culture 
and were used for the production and propagation of the recombinant 
baculoviruses. BTI-TN-5B1-4 (Hi5) cells were grown in monolayer 
under the same conditions and were used for the expression of pro-
teins only. Recombinant baculoviruses were generated, purified and 
propagated according to Sanders et al. [19], and designated rvE6 and 
rvE6-AP. Hi5 cells were infected at a multiplicity of infection of 5 or 
greater and maintained at 27°C for the required length of time. 
2.5. p53 degradation assays 
p53 RNA was transcribed in vitro from linearised pT7p53 and 
translations were performed in rabbit reticulocyte lysate (RLL) or 
wheat germ extract (WGE) (Promega) in the presence of 
[35S]methionine/cysteine (ProMix, Amersham International, pic) ac-
cording to the manufacturers' instructions. To prevent subsequent 
translation, in vitro translation lysates were incubated with RNase 
added to 1 μg/ml at room temperature for 5 min. 2-10 μΐ of p53 
translated in RLL was mixed with 1 μΐ of various dilutions of pure 
E6 (1 mg/ml) and incubated at 30°C for 1 h. WGE degradation assays 
were carried out as described by Huibregtse et al. [11], but with in 
vitro translated HPV 16 E6 and E6-AP replaced by an equivalent 
amount of WGE and the purified proteins. Samples were then mixed 
with 200 μΐ of buffer A (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1% 
(v/v) Nonidet P-40) before immunoprecipitating with anti-p53 anti-
body pAb421 (Oncogene Science). Reaction products were analysed 
by SDS-PAGE and autoradiography. 
2.6. Analysis of protein-protein interactions by chemical crosslinking 
Purified HPV 16 E6, at a concentration of 1 mg/ml, was diluted 1/5 
in 25 mM HEPES, pH 7.9, 1 mM dithiothreitol (DTT), to reduce the 
concentration of NaCl. Proteins, at 200 μg/ml, were incubated on ice 
for 30 min in the presence of 1 mM disuccinimidyl suberate (DSS, 
resuspended in DMSO). Reaction volumes were equated, where nec-
essary, with 25 mM HEPES, pH 7.9, 100 mM NaCl, 1 mM DTT. 
Reactions were quenched by the addition of Tris-HCl, pH 7.5 to a 
final concentration of 50 mM and a further 15 min incubation on ice. 
To carry out crosslinking analysis on insect cell lysates, Hi5 insect 
cells at 48 h post infection were harvested, washed in PBS and lysed 
in lysis buffer (25 mM HEPES, pH 7.9, 100 mM NaCl, 0.5% Nonidet 
P-40, 1 mM DTT, 1 mM phenylmethylsulphonyl fluoride, 1 μΜ pep-
statin, 10 μg/ml E-64) for 20 min before clarifying by centrifugation at 
50000Xg for 20 min at 4°C. Protein concentrations were equated by 
the addition of lysis buffer. Reactions were carried out as above but 
using bis(sulfosuccinimidyl) suberate (BS3, resuspended in dH20) in-
stead of DSS and volumes were equated, where necessary, with lysates 
from wild-type infected insect cells. Protein samples were analysed by 
SDS-PAGE followed by immunoblotting. 
3. Results 
E6 and E6-AP were cloned into the bacterial expression 
vector pET15b via the cloning vector pT7Blue and all clones 
were completely sequenced. They were then expressed in E. 
coli and soluble protein was purified to near homogeneity as 
described in Section 2 (Fig. 1). Recombinant baculoviruses 
expressing E6 and E6-AP were also generated using their re-
spective pVL941 clones. When Hi5 insect cells were infected 
with one of the baculoviruses and expression levels analysed 
by SDS-PAGE and Coomassie staining, proteins migrating at 
the predicted molecular weights for E6 and E6-AP were 
clearly visible (Fig. 1). 
To confirm that the proteins had retained a native, bio-
chemically active conformation, their ability to facilitate p53 
proteolysis was determined. When p53 was translated in retic-
Fig. 1. a: Expression and purification of HPV 16 E6 expressed in 
E. coli, as described in Section 2, analysed on a 15% SDS-polyacryl-
amide gel. Lane 1, molecular weight marker proteins; lane 2, total 
soluble protein from E. coli transformed with рЕТЕб; soluble pro-
tein following: lane 3, immobilised metal affinity chromatography; 
lane 4, thrombin cleavage; lane 5, cation exchange chromatography 
and lane 6, soluble, pure E6 following gel filtration chromatogra-
phy. b: Expression and purification of E6-AP expressed in E. coli 
analysed on a 10% SDS-polyacrylamide gel. Lane 1, molecular 
weight marker proteins; lane 2, total soluble protein from E. coli 
transformed with pETE6-AP; soluble protein following: lane 3, im-
mobilised metal affinity chromatography; lane 4, ammonium sul-
phate precipitation; lane 5, anion exchange chromatography and 
lane 6, soluble, pure E6-AP following gel filtration chromatography. 
c: Expression of E6 and E6-AP in Hi5 insect cells. Insect cells were 
infected with recombinant baculoviruses, harvested at 72 h post in-
fection and total cell protein was analysed by SDS-PAGE on a 15% 
gel. Lane 1, molecular weight marker proteins; lane 2, wild type 
AcMNPV infected cells; lane 3, mock infected cells; lane 4, rvE6 in-
fected cells; lane 5, rvE6-AP infected cells. 
ulocyte lysate, which possesses intrinsic E6-AP activity [10], its 
degradation was induced by the addition of either purified E6 
or E6-containing insect cell lysates (Fig. 2a). When translated 
in WGE, which has no E6-AP activity [10], p53 degradation 
was promoted, as predicted, upon addition of both E6 and 
E6-AP (Fig. 2b). Data are shown for the purified proteins but 
identical results were obtained using insect cell lysates. 
Using the purified, biologically active proteins we set out to 
investigate the interactions of E6 and E6-AP in vitro by em-
ploying chemical crosslinking techniques which would permit 
determination of the molecular weights of complexes formed 
by comparison with molecular weight standards. To enable us 
to manipulate small amounts of protein and to determine the 
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precise components of the complexes formed, the gels were 
subjected to Western analysis. 
When E6 alone was treated with the crosslinker DSS and 
analysed by immunoblotting there was evidence for specific 
dimerisation (Fig. 3a, lane 2). On the addition of E6-AP, a 
high molecular weight band was detected which migrated 
slightly faster than the 140 kDa molecular weight marker 
(Fig. 3a, lane 4). This complex therefore represents the 
E6:E6-AP complex. When a similar analysis was performed 
with E6-AP, followed by immunoblotting with the E6-AP 
antibody, a 100 kDa species corresponding to E6-AP alone 
was identified (Fig. 3b, lane 2). Upon the addition of E6, an 
additional, slower moving band, migrating at 120 kDa, was 
detected which represents the E6:E6-AP complex (Fig. 3b, 
lane 4). These data suggest that E6 and E6-AP interact as 
two monomers despite the ability of purified E6 to form a 
homodimer. 
To establish that the complex identified on combining pu-
rified E6 and E6-AP was specific and not an artifact we 
sought to detect a similar high molecular weight complex in 
a protein lysate where other protein-protein interactions could 
take precedence. Therefore, a similar analysis was carried out 
using lysates from insect cells infected with recombinant ba-
culoviruses expressing biologically active E6 and E6-AP. 
Clearer results were obtained in this system using the water 
soluble analogue of DSS, BS3 (data not shown). 
There was again evidence for formation of an E6 dimer 
when a lysate containing E6 only was treated with crosslinker 
(Fig. 4a, lane 2). However, a higher molecular weight band 
was visible (complex A), running at approximately 100 kDa. 
On combining the lysates from cells infected with rvE6 or 
rvE6-AP a second higher molecular weight band (complex 
B) was detected which migrated more slowly than that present 
with E6 alone (Fig. 4a, lane 6). Complex В ran at the same 
molecular weight by SDS-PAGE as the high molecular weight 
complex observed with the purified proteins. Interestingly, 
complex A was not observed when the same analysis was 
carried out on a lysate that had been coinfected with rvE6 
and rvE6-AP (Fig. 4a, lane 4). If the lysates from the cells 
infected with rvE6 or rvE6-AP were mixed and preincubated, 
Fig. 2. Degradation of in vitro translated p53 induced by E6 and 
E6-AP purified from E. coli, a: p53 was translated in reticulocyte 
lysate and pure E6 was added at dilutions down to 1:500. b: p53 
was translated in WGE and pure E6 and E6-AP were added, as in-
dicated. All reactions were carried out as described in Section 2 and 
analysed by SDS-PAGE on a 12% gel and autoradiography. 
Fig. 3. Crosslinking E6 and E6-AP proteins purified from E. coli, a: 
E6 (lanes 1 and 2) or E6 with E6-AP (lanes 3 and 4) were incu-
bated in the presence of DSS (lanes 2 and 4) or DMSO alone, as a 
control, (lanes 1 and 3). Samples were analysed on a 5-20% gra-
dient gel followed by Western analysis with the E6 specific antise-
rum. b: E6-AP (lanes 1 and 2) or E6 with E6-AP (lanes 3 and 4) 
were incubated in the presence of DSS (lanes 2 and 4) or DMSO 
alone (lanes 1 and 3). Samples were analysed on a 6% gel followed 
by Western analysis with the E6-AP specific antiserum. Positions of 
molecular weight reference markers are indicated. Circles represent 
E6-AP and small ovals represent E6. 
prior to crosslinking, the relative yield of complexes A and В 
was not altered (data not shown). 
When a similar analysis was carried out on lysates express-
ing E6-AP followed by Western analysis with an E6-AP anti-
body (Fig. 4b, lane 2) a major band at 100 kDa was identified, 
as expected. On mixing lysates from rvE6 and rvE6-AP in-
fected cells (Fig. 4b, lanes 5 and 6) or when analysing lysates 
from cells coinfected with both rvE6 and rvE6-AP (Fig. 4b, 
lanes 3 and 4) a novel species, also migrating at the position 
of an E6:E6-AP heterodimer, was detected. 
4. Discussion 
There is much in vitro evidence demonstrating that, during 
the degradation of p53 by the ubiquitin dependent proteolysis 
pathway, E6 and E6-AP function as a ubiquitin protein ligase 
in the ubiquitylation cascade. However, an interaction be-
tween the two proteins has not been demonstrated in vivo 
and the results of previous studies caution a direct correlation 
between in vitro and in vivo data [21]. There are also no direct 
data regarding the stoichiometry of any of these interactions. 
As a result we set out to examine the interactions of HPV 16 
E6 and E6-AP in vitro and ex vivo, i.e. overexpressed in insect 
cells. 
The cDNA of E6-AP was cloned from the cervical carcino-
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Fig. 4. Crosslinking insect cell lysates. a: Lysates from rvE6 infected 
cells (lanes 1 and 2), lysates from cells coinfected with rvE6 and 
rvE6-AP (lanes 3 and 4) or lysates from rvE6 infected cells mixed 
with lysates from rvE6-AP infected cells (lanes 5 and 6) were incu-
bated in the presence of BS3 (lanes 2, 4 and 6) or dH20 (lanes 1, 3 
and 5). Samples were analysed on a 5-20% gradient gel and ana-
lysed by immunoblotting with the E6 antiserum. b: Lysates from 
rvE6-AP infected cells (lanes 1 and 2), lysates from cells coinfected 
with rvE6-AP and rvE6 (lanes 3 and 4) or lysates from rvE6-AP in-
fected cells mixed with lysates from rvE6 infected cells (lanes 5 and 
6) were incubated in the presence of BS3 (lanes 2, 4 and 6) or 
dH20 (lanes 1, 3 and 5). Samples were analysed on a 6% gel and 
analysed by immunoblotting with the E6-AP antiserum. Positions of 
molecular weight reference markers are indicated. Circles represent 
E6-AP, small vertical ovals represent E6 and flat ovals represent a 
cellular or viral protein. 
ma cell line CaSki on the basis that continuous E6 function, 
including the degradation of p53, is required for the mainte-
nance of the neoplastic phenotype in these cells [22,23]. This 
evidence implies that these cells will have a functional E6-AP. 
There are no data regarding expression of the original full 
length cDNA but we were able to overexpress soluble, full 
length protein in E. coli and purify it to virtual homogeneity. 
HPV 16 E6 was also overexpressed in E. coli and soluble 
protein was purified to near homogeneity. Cleavage of the 
short His tag from the protein resulted in a non-fusion prod-
uct, except for 3 amino acids. This is important because most 
of the studies on E6 have involved the use of large, mainly N-
terminal, fusions such as glutathione S-transferase or maltose 
binding protein. It is very likely that these fusion proteins will 
have an effect on the ability of the small, 18 kDa E6 to 
interact with other proteins. These effects could be allosteric 
or simply obstructive. Other workers have also found that E6 
is highly insoluble and as a result have applied denaturation/ 
renaturation techniques to obtain purified protein. It is well 
known that these harsh treatments can, at the very least, 
partially inactivate proteins. 
The presence of a fusion protein could also have a crucial 
effect on the production of antibodies against E6. This could 
be particularly important in the case of an N-terminal fusion 
because the N-terminus of E6 has been demonstrated to be 
highly antigenic [24]. Anti-E6 antibodies are notoriously poor 
and other workers have found that even monoclonal antibod-
ies raised against E6 crossreacted with normal human tissue 
[25]. Although there was still an element of crossreactivity 
with the E6 antiserum described here, it did not crossreact 
with HPV 18 E6 (data not shown). 
To analyse the interactions of E6 and E6-AP by chemical 
crosslinking, crosslinkers were chosen on the basis of their 
spacer arm length (11.4 A), a length that should avoid cross-
linking non-specific interactions without prohibiting those 
that are specific. DSS has also been successfully applied to 
identifying other protein-protein interactions [26] and BS3 is 
its water soluble analogue. Crosslinking analysis of the puri-
fied proteins provides strong evidence for the existence of E6 
dimers, a possibility that has only previously been suggested 
based on indirect evidence [27,28]. E6 does not resolve as a 
dimeric species by size exclusion chromatography (data not 
shown) which may be a consequence of the high salt running 
conditions used. This suggests that the E6 dimers are not very 
stable, especially when compared to the stability of dimers of 
other papillomavirus proteins, such as those formed by BPV 
E2 [29]. 
When pure E6 and E6-AP were crosslinked, a high molec-
ular weight species was observed which corresponds to the 
E6:E6-AP complex. Comparison with molecular weight 
standards indicates that this complex almost certainly repre-
sents one molecule of E6 interacting with one molecule of E6-
AP and is in agreement with the suggestion by Huibregtse et 
al. [11] that the two proteins interact with a ratio of 1:1. 
Although crosslinking can effect the mobility of proteins in 
SDS polyacrylamide gels by producing protein masses with 
unusual shapes, the small size of E6 relative to E6-AP signifi-
cantly reduces this possibility. The doublet at the position of 
the E6:E6-AP complex in Fig. 3b probably represents two 
isoforms of the complex as a result of differential crosslinking. 
The crosslinking experiments with insect cell lysates, where 
non-specific contacts between E6 and E6-AP should be elim-
inated and any post-translational modifications of the pro-
teins will occur, was used to confirm the specificity of the 
results seen with the purified proteins and to show that the 
same interactions take place in vivo. Crosslinking of lysates 
from cells expressing only E6 provided further evidence for 
the formation of an E6 dimer and confirms the specificity of 
the interaction detected with the pure protein (Fig. 4a). How-
ever, it indicated the preference for other protein:protein in-
teractions in vivo as complex A presumably represents a com-
plex of E6 with another cellular or viral protein. Although 
complex A was still present when lysates from cells expressing 
E6 or E6-AP were mixed together and analysed, there was 
also evidence for the E6:E6-AP complex (complex B). This 
high molecular weight species migrated to the same position 
as that seen with the crosslinked purified proteins. The ratio 
of these two complexes did not change with time of preincu-
bation suggesting that both complexes were stable. Interest-
ingly, when a lysate from cells coinfected with both rvE6 and 
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rvE6-AP was subjected to the same analysis only the E6:E6-
A P complex (complex B) was evident and complex A was not 
observed. This suggests that when E6 is cotranslated with E6-
AP, it preferentially forms a complex with E6-AP rather than 
with the cellular/viral protein. Alternatively, this observation 
may be a consequence of intracellular localisation of the pro-
teins. If the cellular/viral protein is localised to a different 
compartment of the cell then it is possible that it only inter-
acts with E6 once the cells are lysed. In contrast, assuming 
that E6 and E6-AP are colocalised in the cell, their complex 
may have preformed before the cell lysis and remained stable 
throughout the experiment. These possibilities can be inves-
tigated by carrying out a crosslinking analysis on the intact 
cells. Results obtained by crosslinking lysates and then ana-
lysing for the presence of E6-AP further confirmed the exist-
ence of the E6:E6-AP heterodimer (Fig. 4b). 
The literature provides several examples of studies which 
have attempted to identify other proteins with which E6 in-
teracts and/or alternative purposes for the protein. However, 
the only well understood function of E6, to date, is its ca-
pacity to accelerate the degradation of p53. The ability of 
single molecules of E6 and E6-AP to interact to form a het-
erodimer, both in vivo and in vitro, alongside the potential for 
E6 to form dimers, provides support for the possibility that 
E6 plays a further role in the life cycle of HPV, other than the 
degradation of p53, and that these other functions may de-
pend upon supramolecular structural differences of the pro-
tein. The proteins and antibodies described here will be useful 
in further structural, functional and biochemical analyses of 
E6 and E6-AP and also in the study of their interactions with 
p53. Furthermore, chemical crosslinking may provide an al-
ternative method for identifying the other proteins which in-
teract with E6. 
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